Overview
RLAY market data
Price History
RLAY price chart · 1M
- O
- 17.28
- H
- 17.54
- L
- 17.16
- C
- 17.31
- Vol
- 129,434.00
Daily history from Jul 16, 2020
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $17.28
- Previous Close
- $17.06
- Day High
- $17.54
- Day Low
- $17.16
- 52 Week High
- $21.15
- 52 Week Low
- $5.98
- 7 Day Return
- -0.57%
- 30 Day Return
- -8.80%
- 90 Day Return
- -13.04%
- 1 Year Return
- +161.48%
- Daily Notional Volume
- $2.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.61 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.70 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,047.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.85 – $21.27 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.7B · P/B 2.59 · P/S 361.64.
Company News
8 captured
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment OptionGlobenewswire Inc ·
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobenewswire Inc ·